Key result
Antithrombin III combined with low-dose heparin limits VTE to ~7% after total hip replacement.
Why the study?
Does antithrombin III combined with low-dose heparin prevent venous thromboembolic disease in patients undergoing total hip or knee replacement?
Population
Patients undergoing total hip replacement or total knee replacement
Comparison
Antithrombin III replacement in combination with… vs Dextran 40 (in the hip replacement trial)
Design
RCT, Randomized prospective
Follow-up
Postoperative
Authors
Loading...
Supports antithrombin III plus low-dose heparin for VTE prophylaxis after hip replacement; confirms benefit in postoperative orthopedic patients.
RCT
Randomized
Does antithrombin III combined with low-dose heparin prevent venous thromboembolic disease in patients undergoing total hip or knee replacement?
Antithrombin III replacement combined with low-dose heparin is an effective prophylactic regimen for preventing venous thromboembolic disease following total hip replacement.
Francis et al. (1989) conducted an RCT in Venous thromboembolic disease after total hip or total knee replacement. Antithrombin III (ATIII) and low-dose heparin vs. Dextran 40 was evaluated on Incidence of venous thromboembolic disease. Antithrombin III combined with low-dose heparin was an effective prophylactic regimen following total hip replacement, resulting in a 7% incidence of venous thromboembolic disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: